

Vaccine Technology II

ECI Symposium Series, Volume P9

**Albufeira, Algarve, Portugal
1-6 June 2008**

ISBN: 978-1-60560-997-3

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© (2008) by Engineering Conferences International
All rights reserved.

Printed by Curran Associates, Inc. (2009)

For permission requests, please contact Engineering Conferences International
at the address below.

Engineering Conferences International
32 Broadway, Suite 314
New York, NY 10004

Phone: (212) 514-6760
Fax: (212) 514-6030

info@engconfintl.org

Additional copies of this publication are available from:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571 USA
Phone: 845-758-0400
Fax: 845-758-2634
Email: curran@proceedings.com
Web: www.proceedings.com

TABLE OF CONTENTS

SESSION I: IMMUNE SYSTEM FUNCTION AND ITS QUANTITATION

Quality Issues: The Good Enough Vaccine	1
<i>Philip Minor</i>	

SESSION II: VIRUS AND REPLICON VECTORED VACCINES

Towards a Therapeutic HCV Vaccine - A Preclinical and Clinical Learning Curve	20
<i>Alexander von Gabain</i>	
VEEV Replicon-Based Vaccines used in Heterologous Prime Boost Strategies Induce Lifelong Protection Against Prostate Crapy of Cervical Cancer in Mice and Robust Cell-Mediated Immunity in Rhesus Macaques	50
<i>W. Martin Kast</i>	

SESSION III: EMERGENT & EMERGENCY VACCINES

FluvBlok, A High Dose Recombinant Hemagglutinin Influenza Vaccine	76
<i>Manon Cox</i>	
Challenges and Solutions for the Next Generation of Vaccines: Development of Cell Culture-Based Live Attenuated Influenza Vaccine	106
<i>Jonathan Liu, Luis Maranga, Sachin Mani, Richard Schwartz</i>	

SESSION IV: CONJUGATE VACCINES

Analytical and Manufacturing Challenges: Preparation of Bacterial Polysaccharide Conjugates	135
<i>Carl E. Frasch</i>	
Development of Validated Assays for Measuring the Human Antibody Response to Polysaccharide Conjugate Vaccines	155
<i>Helena Kayhty</i>	

SESSION V: ADJUVANTS & FORMULATION

Development of Vaxfectin - Adjuvanted DNA Vaccines	196
<i>Alain Rolland</i>	

SESSION VI: CHARACTERIZATION OF COMPLEX BIOLOGICALS

Well-Characterized Adenoviral Vector-based Vaccines: Are We There Yet?	224
<i>Katey Einterz Owen</i>	
Focus on Aggregation: Causes, Impact & Characterization	255
<i>John Philo</i>	
Challenge of Filing 4 New Vaccines at Once - Lessons Learned	290
<i>Keith Chirgwin</i>	

SESSION VII: VLP'S & INACTIVATED VACCINES

RSV Vaccine Using Recombinant F Protein?	309
<i>Sophie Nallet, Iwo Konig, Nicole Westerfeld, Lucia Baldi, Mario Amacker, David Hacker, Christiane Zaborosch, Rinaldo Zurbriggen, Florian Wurm</i>	
A Selective Recovery Methodology for the Primary Purification of Lipid Envelope Virus-Like Particles from <i>S. Cerevisiae</i>	326
<i>Gaik Sui Kee, Hari Pujar, Nigel Titchener-Hooker</i>	

SESSION VIII: VETERINARY VACCINES: LESSONS TO LEARN FOR HUMAN VACCINE DEVELOPMENT

Emerging Diseases, Zoonoses and Vaccines to Control Them	343
<i>Paul-Pierre Pastoret</i>	

SESSION IX: MANUFACTURING OF VACCINES

Process Intensification for Large Scale Manufacturing Issues	388
<i>J. C. Drugmand, N. Havelange, N. Alau, J. Castillo</i>	
Trouble-Shooting Fermentation and Primary Recovery Manufacturing Issues in Order to Optimize Antigen Expression for the Vaccine Business	429
<i>Tim Lee</i>	

SESSION X: VACCINES IN DEVELOPING COUNTRIES

Vaccine Development for Developing Countries - Regulatory Approach in the European Union	441
<i>Manfred G. Haase</i>	
Developing Vaccines for Neglected Diseases	465
<i>Douglas Holtzman</i>	
Abstracts	487
Author Index	